These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095 [TBL] [Abstract][Full Text] [Related]
32. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094 [TBL] [Abstract][Full Text] [Related]
33. Positron Emission Tomography with [ Hamzaoui M; Garcia J; Boffa G; Lazzarotto A; Absinta M; Ricigliano VAG; Soulier T; Tonietto M; Gervais P; Bissery A; Louapre C; Bottlaender M; Bodini B; Stankoff B Ann Neurol; 2023 Aug; 94(2):366-383. PubMed ID: 37039158 [TBL] [Abstract][Full Text] [Related]
34. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS. Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933 [TBL] [Abstract][Full Text] [Related]
35. Retinal nerve fiber and ganglion cell complex layer thicknesses mirror brain atrophy in patients with relapsing-remitting multiple sclerosis. Glasner P; Sabisz A; Chylińska M; Komendziński J; Wyszomirski A; Karaszewski B Restor Neurol Neurosci; 2022; 40(1):35-42. PubMed ID: 35180139 [TBL] [Abstract][Full Text] [Related]
36. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI. Coll L; Pareto D; Carbonell-Mirabent P; Cobo-Calvo Á; Arrambide G; Vidal-Jordana Á; Comabella M; Castilló J; Rodríguez-Acevedo B; Zabalza A; Galán I; Midaglia L; Nos C; Salerno A; Auger C; Alberich M; Río J; Sastre-Garriga J; Oliver A; Montalban X; Rovira À; Tintoré M; Lladó X; Tur C Neuroimage Clin; 2023; 38():103376. PubMed ID: 36940621 [TBL] [Abstract][Full Text] [Related]
37. The impact of deep grey matter volume on cognition in multiple sclerosis. Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200 [TBL] [Abstract][Full Text] [Related]
38. Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis. Fujimori J; Nakashima I J Neuroimmunol; 2024 Feb; 387():578280. PubMed ID: 38171046 [TBL] [Abstract][Full Text] [Related]
39. Gray matter atrophy is related to long-term disability in multiple sclerosis. Fisniku LK; Chard DT; Jackson JS; Anderson VM; Altmann DR; Miszkiel KA; Thompson AJ; Miller DH Ann Neurol; 2008 Sep; 64(3):247-54. PubMed ID: 18570297 [TBL] [Abstract][Full Text] [Related]
40. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]